RÉSUMÉ
Long-term ß-adrenoceptor (ß-AR) stimulation is a pathological mechanism associated with cardiovascular diseases resulting in endothelial and perivascular adipose tissue (PVAT) dysfunction. In this study, we aimed to identify whether ß-adrenergic signaling has a direct effect on PVAT. Thoracic aorta PVAT was obtained from male Wistar rats and cultured ex vivo with the ß-AR agonist isoproterenol (Iso; 1â µM) or vehicle for 24 hours. Conditioned culture medium (CCM) from Iso-treated PVAT induced a marked increase in aorta contractile response, induced oxidative stress, and reduced nitric oxide production in PVAT compared to vehicle. In addition, Iso-treated PVAT and PVAT-derived differentiated adipocytes exhibited higher corticosterone release and protein expression of 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1), an enzyme responsible for de novo synthesis of corticosterone. Macrophages exposed to Iso also exhibited increased corticosterone release in response to ß-AR stimulation. Incubation of Iso-treated PVAT and PVAT-derived differentiated adipocytes with ß3-AR antagonist restored aorta contractile function modulated by Iso-CCM and normalized 11ß-HSD1 protein expression. These results show that ß3-AR signaling leads to upregulation of 11ß-HSD1 in PVAT, thus increasing corticosterone release and contributing to impair the anticontractile function of this tissue.
Sujet(s)
11-beta-Hydroxysteroid dehydrogenase type 1 , Corticostérone , Isoprénaline , Animaux , Mâle , Rats , 11-beta-Hydroxysteroid dehydrogenase type 1/métabolisme , 11-beta-Hydroxysteroid dehydrogenase type 1/génétique , Adipocytes/métabolisme , Adipocytes/effets des médicaments et des substances chimiques , Tissu adipeux/métabolisme , Agonistes bêta-adrénergiques/pharmacologie , Aorte thoracique/effets des médicaments et des substances chimiques , Aorte thoracique/métabolisme , Corticostérone/métabolisme , Milieux de culture conditionnés/pharmacologie , Isoprénaline/pharmacologie , Monoxyde d'azote/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Rat Wistar , Récepteurs bêta-adrénergiques/métabolismeRÉSUMÉ
Objective: Thoracic perivascular adipose tissue (PVAT) has been shown to release factors that influence the functioning of neighboring vascular tissue. Cardiovascular complications of obesity are on the rise; therefore, this study set out to determine if adipose-specific ablation of vascular endothelial growth factor-A (VEGF-A) plays a role in the maintenance of aortic structure and function. Methods: Adipose-specific VEGF-A-deficient mice were previously generated. Fabp4cre(+). VEGF flox/flox and Fabp4cre(-). VEGF flox/flox mice were maintained on chow diet. PVAT gene expression was measured with real-time quantitative PCR. Aortic vasomotor response was assessed with isometric tension measurements. Collagen deposition was analyzed histologically in the vascular media and compared using ratiometric pigment density. Results: PVAT-specific adiponectin expression was decreased in Fabp4cre(+). VEGF flox/flox mice. Isometric tension measurements revealed a dose-dependent dysfunction in response to acetylcholine within the distal aortic segment of Fabp4cre(+). VEGF flox/flox . Fabp4cre(+). VEGF flox/flox mice exhibited increased aortic deposition of collagen within the thoracic adventitial and medial spaces. Conclusion: These data demonstrate that decreased expression of VEGF-A within the surrounding adipose tissue microenvironment of the thoracic aorta has a detrimental effect on aortic integrity and vascular function. Modulation of angiogenic pathways within PVAT may offer an important avenue toward the treatment of adipose tissue dysfunction in obesity and its vascular complications.
RÉSUMÉ
BACKGROUND: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic inflammation of the joints, leading to bone erosion and joint dysfunction. Despite the recent successes of disease-modifying anti-rheumatic drugs (DMARDs), there is still clinical need for understanding the development and molecular etiology of RA. Wnts are developmental morphogens whose roles in adult pathology are poorly characterized. Wnt5a is a member of the non-canonical family of Wnts that modulates a wide range of cell processes, including differentiation, migration, and inflammation. Wnt5a has been implicated as a possible contributor to arthritis and it is upregulated in synovial fibroblasts from RA patients. METHODS: We investigated the role of endogenous Wnt5a in RA. Tamoxifen-inducible, Wnt5a knockout (Wnt5a cKO) mice and littermate controls were monitored for arthritis development and joint pathology using the K/BxN serum transfer-induced arthritis (STIA) model. To explore a role of Wnt5a in osteoclast fusion, bone marrow-derived monocytes (BMDMs) were differentiated in vitro. RESULTS: Wnt5a cKO mice were resistant to arthritis development compared to control littermates as assessed by ankle thickness and histologic measurements. Some parameters of inflammation were reduced in the Wnt5a cKO mice, including the extent of polymononuclear cell infiltration and extra-articular inflammation. Wnt5a cKO mice also exhibited less cartilage destruction and a reduction in osteoclast activity with concomitant reduction in tartrate-resistant acid phosphatase (TRAP), cathepsin K (CTSK), macrophage colony-stimulating factor (MCSF), matrix metalloproteinase (MMP)2 and MMP9 in the arthritic joints. Treatment of BMDMs with Wnt5a enhanced osteoclast fusion and increased the expression of dendrocyte-expressed seven transmembrane protein (DCSTAMP) and MMP9, that are necessary for osteoclast formation and activity. CONCLUSIONS: These data suggest that Wnt5a modulates the development of arthritis by promoting inflammation and osteoclast fusion, and provide the first mouse genetic evidence of a role for endogenous Wnt5a in autoimmune disease.
Sujet(s)
Arthrite expérimentale/génétique , Polyarthrite rhumatoïde/génétique , Protéine Wnt-5a/déficit , Animaux , Arthrite expérimentale/anatomopathologie , Polyarthrite rhumatoïde/anatomopathologie , Modèles animaux de maladie humaine , Souris , Souris knockoutRÉSUMÉ
BAT-controlled thermogenic activity is thought to be required for its capacity to prevent the development of insulin resistance. This hypothesis predicts that mediators of thermogenesis may help prevent diet-induced insulin resistance. We report that the mitochondrial fusion protein Mitofusin 2 (Mfn2) in BAT is essential for cold-stimulated thermogenesis, but promotes insulin resistance in obese mice. Mfn2 deletion in mice through Ucp1-cre (BAT-Mfn2-KO) causes BAT lipohypertrophy and cold intolerance. Surprisingly however, deletion of Mfn2 in mice fed a high fat diet (HFD) results in improved insulin sensitivity and resistance to obesity, while impaired cold-stimulated thermogenesis is maintained. Improvement in insulin sensitivity is associated with a gender-specific remodeling of BAT mitochondrial function. In females, BAT mitochondria increase their efficiency for ATP-synthesizing fat oxidation, whereas in BAT from males, complex I-driven respiration is decreased and glycolytic capacity is increased. Thus, BAT adaptation to obesity is regulated by Mfn2 and with BAT-Mfn2 absent, BAT contribution to prevention of insulin resistance is independent and inversely correlated to whole-body cold-stimulated thermogenesis.
Sujet(s)
Tissu adipeux brun/métabolisme , dGTPases/déficit , dGTPases/génétique , Insulinorésistance , Thermogenèse/génétique , Animaux , Alimentation riche en graisse , Métabolisme énergétique , Femelle , Glycolyse , Mâle , Souris , Mitochondries/métabolisme , Protéines mitochondriales/métabolisme , ObésitéRÉSUMÉ
Brown-like adipocytes exist in several adipose depots including white (WAT) as well as brown (BAT). Activation of these UCP1+ cells is a potential therapeutic strategy to combat obesity. Studies have shown that posttranslational modifications of PPARγ regulate select adipocyte programs. Deacetylation of K268 and K293 in the ligand-binding domain of PPARγ by Sirt1 induces browning of WAT. Phosphorylation of S273 of PPARγ by CDK5 or ERK stimulates a diabetogenic program of gene expression in WAT. Here, we report that roscovitine, a CDK inhibitor, prevents S273 phosphorylation and promotes formation of UCP1+ (brite) adipocytes in WAT. It also enhances energy expenditure as well as prevents diet-induced obesity and insulin resistance. Analysis of fluorescence-activated cell-sorted UCP1+ adipocytes shows that the mRNA signature of brite adipocytes is distinct from beige adipocytes, which arise through catecholamine signaling. These results suggest that brown-like adipocytes in WAT may arise from multiple origins.
Sujet(s)
Adipocytes/métabolisme , Tissu adipeux brun/métabolisme , Tissu adipeux blanc/métabolisme , Purines/pharmacologie , Protéine-1 de découplage/métabolisme , Adipocytes/effets des médicaments et des substances chimiques , Tissu adipeux brun/effets des médicaments et des substances chimiques , Tissu adipeux blanc/effets des médicaments et des substances chimiques , Animaux , Régime alimentaire , Métabolisme énergétique/effets des médicaments et des substances chimiques , Cytométrie en flux , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Génome , Intolérance au glucose/métabolisme , Intolérance au glucose/anatomopathologie , Insulinorésistance , Mâle , Souris de lignée C57BL , Obésité/métabolisme , Obésité/anatomopathologie , Récepteur PPAR gamma/métabolisme , Phosphorylation/effets des médicaments et des substances chimiques , Agents protecteurs/pharmacologie , ARN messager/génétique , ARN messager/métabolisme , Roscovitine , Sérine/métabolisme , Thermogenèse/effets des médicaments et des substances chimiques , Protéine-1 de découplage/génétiqueRÉSUMÉ
BACKGROUND: Despite the increasing prevalence of heart failure with preserved ejection fraction (HFpEF) in humans, there are no evidence-based therapies for HFpEF. Clinical studies suggest a relationship between obesity-associated dysfunctional adipose tissue (AT) and HFpEF. However, an apparent obesity paradox exists in some HF populations with a higher body mass index. We sought to determine whether HFpEF exerted effects on AT and investigated the involved mechanisms. METHODS AND RESULTS: Mice underwent d-aldosterone infusion, uninephrectomy, and were given 1% saline for 4 weeks. HFpEF mice developed hypertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriuretic peptide expression. Although body weights were similar in HFpEF and sham-operated mice, white AT was significantly smaller in HFpEF than in sham (epididymal AT, 7.59 versus 10.67 mg/g; inguinal AT, 6.34 versus 8.38 mg/g). These changes were associated with smaller adipocyte size and increased beiging markers (ucp-1, cidea, and eva) in white AT. Similar findings were seen in HFpEF induced by transverse aortic constriction. Increased activation of natriuretic peptide signaling was seen in white AT of HFpEF mice. The ratio of the signaling receptor, natriuretic peptide receptor type A, to the clearance receptor, nprc, was increased as was p38 mitogen-activated protein kinase activation. However, HFpEF mice failed to regulate body temperature during cold temperature exposure. In HFpEF, despite a larger brown AT mass (5.96 versus 4.50 mg/g), brown AT showed reduced activity with decreased uncoupling protein 1 (ucp-1), cell death-inducing DFFA-like effector a (cidea), and epithelial V-like antigen (eva) expression and decreased expression of lipolytic enzymes (hormone-sensitive lipase, lipoprotein lipase, and fatty acid binding protein 4) versus sham. CONCLUSIONS: These findings show that HFpEF is associated with beiging in white AT and with dysfunctional brown AT.
Sujet(s)
Tissu adipeux brun/physiopathologie , Tissu adipeux blanc/physiopathologie , Défaillance cardiaque/physiopathologie , Débit systolique , Fonction ventriculaire gauche , Adipocytes bruns/métabolisme , Adipocytes bruns/anatomopathologie , Adipocytes blancs/métabolisme , Adipocytes blancs/anatomopathologie , Tissu adipeux brun/métabolisme , Tissu adipeux brun/anatomopathologie , Tissu adipeux blanc/métabolisme , Tissu adipeux blanc/anatomopathologie , Aldostérone , Animaux , Marqueurs biologiques/métabolisme , Régulation de la température corporelle , Modèles animaux de maladie humaine , Fibrose , Défaillance cardiaque/induit chimiquement , Défaillance cardiaque/métabolisme , Défaillance cardiaque/anatomopathologie , Hypertension artérielle/induit chimiquement , Hypertension artérielle/physiopathologie , Hypertrophie ventriculaire gauche/induit chimiquement , Hypertrophie ventriculaire gauche/physiopathologie , Médiateurs de l'inflammation/métabolisme , Souris de lignée C57BL , Myocytes cardiaques/métabolisme , Myocytes cardiaques/anatomopathologie , Néphrectomie , Stress oxydatif , Phénotype , Transduction du signal , Facteurs temps , Dysfonction ventriculaire gauche/induit chimiquement , Dysfonction ventriculaire gauche/physiopathologieRÉSUMÉ
OBJECTIVE: The obesity epidemic in the United States, as well as the accompanying condition of type 2 diabetes, puts a majority of the population at an increased risk of developing cardiovascular diseases including coronary artery disease, stroke, and myocardial infarction. In contrast to white adipose tissue (WAT), brown adipose tissue (BAT) is well vascularized, rich in mitochondria, and highly oxidative. While it is known that the angiogenic factor VEGF-A is required for brown adipocyte development, the functional consequences and exact mechanism remain to be elucidated. Here, we show that VEGF-A plays an essential autocrine role in the function of BAT. MATERIALS AND METHODS: Mouse models were generated with an adipose-specific and macrophage-specific ablation of VEGF-A. Adipose tissue characteristics and thermogenic response were analyzed in vivo, and mitochondrial morphology and oxidative respiration were analyzed in vitro to assess effects of endogenous VEGF-A ablation. RESULTS: VEGF-A expression levels are highest in adipocyte precursors compared to immune or endothelial cell populations within both WAT and BAT. Loss of VEGF-A in adipocytes, but not macrophages, results in decreased adipose tissue vascularization, with remarkably diminished thermogenic capacity in vivo. Complete ablation of endogenous VEGF-A decreases oxidative capacity of mitochondria in brown adipocytes. Further, acute ablation of VEGF-A in brown adipocytes in vitro impairs mitochondrial respiration, despite similar mitochondrial mass compared to controls. CONCLUSION: These data demonstrate that VEGF-A serves to orchestrate the acquisition of thermogenic capacity of brown adipocytes through mitochondrial function in conjunction with the recruitment of blood vessels.
Sujet(s)
Adipocytes bruns/métabolisme , Mitochondries/physiologie , Facteur de croissance endothéliale vasculaire de type A/physiologie , Adipocytes bruns/composition chimique , Animaux , Souris , Spécificité d'organe , Facteur de croissance endothéliale vasculaire de type A/analyseRÉSUMÉ
OBJECTIVE: Polymorphisms in the transcription factor interferon regulatory factor 5 (IRF5) are associated with an increased risk of developing rheumatoid arthritis (RA). This study was undertaken to determine the role of IRF5 in a mouse model of arthritis development. METHODS: K/BxN serum-transfer arthritis was induced in mice deficient in IRF5, or lacking IRF5 only in myeloid cells, and arthritis severity was evaluated. K/BxN arthritis was also induced in mice deficient in TRIF, Toll-like receptor 2 (TLR2), TLR3, TLR4, and TLR7 to determine the pathways through which IRF5 might promote arthritis. In vitro studies were performed to determine the role of IRF5 in interleukin-1 (IL-1) receptor and TLR signaling. RESULTS: Arthritis severity was reduced in IRF5-deficient, TRIF-deficient, TLR3-deficient, and TLR7-deficient mice. The expression of multiple genes regulating neutrophil recruitment or function and bioactive IL-1ß formation was reduced in the joints during active arthritis in IRF5-deficient mice. In vitro studies showed that TLR7 and the TRIF-dependent TLR3 pathway induce proinflammatory cytokine production in disease-relevant cell types in an IRF5-dependent manner. CONCLUSION: Our findings indicate that IRF5 contributes to disease pathogenesis in inflammatory arthritis. This is likely due at least in part to the role of IRF5 in mediating proinflammatory cytokine production downstream of TLR7 and TLR3. Since TLR7 and TLR3 are both RNA-sensing TLRs, this suggests that endogenous RNA ligands present in the inflamed joint promote arthritis development. These findings may be relevant to human RA, since RNA capable of activating TLR7 and TLR3 is present in synovial fluid and TLR7 and TLR3 are up-regulated in the joints of RA patients.
Sujet(s)
Protéines adaptatrices du transport vésiculaire/génétique , Arthrite expérimentale/génétique , Polyarthrite rhumatoïde/génétique , Facteurs de régulation d'interféron/génétique , Glycoprotéines membranaires/génétique , Cellules myéloïdes/métabolisme , Récepteur de type Toll-3/génétique , Récepteur de type Toll-7/génétique , Protéines adaptatrices du transport vésiculaire/immunologie , Animaux , Arthrite expérimentale/immunologie , Polyarthrite rhumatoïde/immunologie , Modèles animaux de maladie humaine , Techniques de knock-down de gènes , Techniques in vitro , Facteurs de régulation d'interféron/immunologie , Interleukine-1 bêta/génétique , Interleukine-1 bêta/immunologie , Glycoprotéines membranaires/immunologie , Souris , Souris de lignée C57BL , Souris knockout , Récepteurs à l'interleukine-1/génétique , Récepteurs à l'interleukine-1/immunologie , Indice de gravité de la maladie , Transduction du signal , Synovie/immunologie , Synovie/métabolisme , Récepteur de type Toll-2/génétique , Récepteur de type Toll-2/immunologie , Récepteur de type Toll-3/immunologie , Récepteur de type Toll-4/génétique , Récepteur de type Toll-4/immunologie , Récepteur de type Toll-7/immunologieRÉSUMÉ
Obesity is a risk factor for cardiovascular disease. C1q/tumor necrosis factor-related protein 9 (CTRP9) is an adipokine that is downregulated by obesity. We investigated the role of CTRP9 in cardiac injury with loss-of-function genetic manipulations and defined the receptor-mediated signaling pathway downstream of this adipokine. CTRP9-knockout (CTRP9-KO) mice at the age of 12 weeks were indistinguishable from wild-type (WT) mice under basal conditions. CTRP9-KO mice had exacerbated contractile left ventricle dysfunction following intraperitoneal injection of lipopolysaccharide (LPS) compared to WT mice. Administration of LPS to CTRP9-KO mice also resulted in increased expression of proinflammatory cytokines and oxidative stress markers in the heart compared to WT mice. Likewise, CTRP9-KO mice showed increased myocardial infarct size and elevated expression of inflammatory mediators in ischemic heart following ischemia and reperfusion compared to WT mice. Treatment of cardiac myocytes with CTRP9 protein led to suppression of LPS-induced expression of proinflammatory genes, which was reversed by blockade of AMPK or ablation of adiponectin receptor I (AdipoR1). Systemic delivery of CTRP9 attenuated LPS-induced cardiac dysfunction in WT mice but not in muscle-specific transgenic mice expressing dominant-negative mutant form of AMPK or in AdipoR1-knockout mice. CTRP9 protects against acute cardiac damage in response to pathological stimuli by suppressing inflammatory reactions through AdipoR1/AMPK-dependent mechanisms.
Sujet(s)
AMP-Activated Protein Kinases/immunologie , Adiponectine/immunologie , Glycoprotéines/immunologie , Lésion de reperfusion myocardique/immunologie , Lésion de reperfusion myocardique/anatomopathologie , Myocarde/anatomopathologie , Récepteurs à l'adiponectine/immunologie , Adiponectine/génétique , Animaux , Cellules cultivées , Glycoprotéines/génétique , Inflammation/complications , Inflammation/génétique , Inflammation/immunologie , Inflammation/anatomopathologie , Lipopolysaccharides/administration et posologie , Lipopolysaccharides/immunologie , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Lésion de reperfusion myocardique/complications , Lésion de reperfusion myocardique/génétique , Myocarde/immunologie , Myocytes cardiaques/immunologie , Myocytes cardiaques/anatomopathologie , RatsRÉSUMÉ
ES-62 is an anti-inflammatory phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae. Accelerated atherosclerosis frequently occurs in systemic lupus erythematosus, resulting in substantial cardiovascular morbidity and mortality. We examined the effects of ES-62 in the gld.apoE(-/-) mouse model of this condition. Treatment with ES-62 did not substantially modulate renal pathology but caused decreased anti-nuclear autoantibody levels. Moreover, a striking 60% reduction in aortic atherosclerotic lesions was observed, with an associated decrease in macrophages and fibrosis. We believe that these latter findings constitute the first example of a defined parasitic worm product with therapeutic potential in atherosclerosis: ES-62-based drugs may represent a novel approach to control accelerated atherosclerosis in systemic lupus erythematosus.
Sujet(s)
Athérosclérose/prévention et contrôle , Protéines d'helminthes/administration et posologie , Facteurs immunologiques/administration et posologie , Lupus érythémateux disséminé/complications , Animaux , Anticorps antinucléaires/sang , Athérosclérose/anatomopathologie , Modèles animaux de maladie humaine , Fibrose/anatomopathologie , Macrophages/immunologie , Mâle , Souris , Souris knockoutRÉSUMÉ
Premature atherosclerosis is a severe complication of lupus and other systemic autoimmune disorders. Gain-of-function polymorphisms in IFN regulatory factor 5 (IRF5) are associated with an increased risk of developing lupus, and IRF5 deficiency in lupus mouse models ameliorates disease. However, whether IRF5 deficiency also protects against atherosclerosis development in lupus is not known. In this study, we addressed this question using the gld.apoE(-/-) mouse model. IRF5 deficiency markedly reduced lupus disease severity. Unexpectedly, despite the reduction in systemic immune activation, IRF5-deficient mice developed increased atherosclerosis and also exhibited metabolic dysregulation characterized by hyperlipidemia, increased adiposity, and insulin resistance. Levels of the atheroprotective cytokine IL-10 were reduced in aortae of IRF5-deficient mice, and in vitro studies demonstrated that IRF5 is required for IL-10 production downstream of TLR7 and TLR9 signaling in multiple immune cell types. Chimera studies showed that IRF5 deficiency in bone marrow-derived cells prevents lupus development and contributes in part to the increased atherosclerosis. Notably, IRF5 deficiency in non-bone marrow-derived cells also contributes to the increased atherosclerosis through the generation of hyperlipidemia and increased adiposity. Together, our results reveal a protective role for IRF5 in lupus-associated atherosclerosis that is mediated through the effects of IRF5 in both immune and nonimmune cells. These findings have implications for the proposed targeting of IRF5 in the treatment of autoimmune disease as global IRF5 inhibition may exacerbate cardiovascular disease in these patients.
Sujet(s)
Athérosclérose/étiologie , Facteurs de régulation d'interféron/immunologie , Lupus érythémateux disséminé/immunologie , Syndrome métabolique X/étiologie , Animaux , Athérosclérose/immunologie , Modèles animaux de maladie humaine , Femelle , Cytométrie en flux , Facteurs de régulation d'interféron/déficit , Lupus érythémateux disséminé/complications , Lupus érythémateux disséminé/anatomopathologie , Mâle , Syndrome métabolique X/immunologie , Souris , Souris de lignée C57BL , Souris knockout , Réaction de polymérisation en chaine en temps réel , RT-PCRRÉSUMÉ
Adipose tissue dysfunction plays a pivotal role in the development of insulin resistance in obese individuals. Cell culture studies and gain-of-function mouse models suggest that canonical Wnt proteins modulate adipose tissue expansion. However, no genetic evidence supports a role for endogenous Wnt proteins in adipose tissue dysfunction, and the role of noncanonical Wnt signaling remains largely unexplored. Here we provide evidence from human, mouse, and cell culture studies showing that Wnt5a-mediated, noncanonical Wnt signaling contributes to obesity-associated metabolic dysfunction by increasing adipose tissue inflammation. Wnt5a expression is significantly upregulated in human visceral fat compared with subcutaneous fat in obese individuals. In obese mice, Wnt5a ablation ameliorates insulin resistance, in parallel with reductions in adipose tissue inflammation. Conversely, Wnt5a overexpression in myeloid cells augments adipose tissue inflammation and leads to greater impairments in glucose homeostasis. Wnt5a ablation or overexpression did not affect fat mass or adipocyte size. Mechanistically, Wnt5a promotes the expression of proinflammatory cytokines by macrophages in a Jun NH2-terminal kinase-dependent manner, leading to defective insulin signaling in adipocytes. Exogenous interleukin-6 administration restores insulin resistance in obese Wnt5a-deficient mice, suggesting a central role for this cytokine in Wnt5a-mediated metabolic dysfunction. Taken together, these results demonstrate that noncanonical Wnt signaling contributes to obesity-induced insulin resistance independent of adipose tissue expansion.
Sujet(s)
Graisse intra-abdominale/métabolisme , Obésité/métabolisme , Graisse sous-cutanée/métabolisme , Voie de signalisation Wnt/physiologie , Animaux , Glucose/métabolisme , Humains , Inflammation/métabolisme , Insulinorésistance , Macrophages/métabolisme , Souris , PhosphorylationRÉSUMÉ
Adiponectin is a well described anti-inflammatory adipokine that is highly abundant in serum. Previous reports have found that adiponectin deficiency promotes cardiovascular and metabolic dysfunction in murine models, whereas its overexpression is protective. Two candidate adiponectin receptors, AdipoR1 and AdipoR2, are uncharacterized with regard to cardiovascular tissue homeostasis, and their in vivo metabolic functions remain controversial. Here we subjected AdipoR1- and AdipoR2-deficient mice to chronic hind limb ischemic surgery. Blood flow recovery in AdipoR1-deficient mice was similar to wild-type; however, revascularization in AdipoR2-deficient mice was severely attenuated. Treatment with adiponectin enhanced the recovery of wild-type mice but failed to rescue the impairment observed in AdipoR2-deficient mice. In view of this divergent receptor function in the hind limb ischemia model, AdipoR1- and AdipoR2-deficient mice were also evaluated in a model of diet-induced obesity. Strikingly, AdipoR1-deficient mice developed severe metabolic dysfunction compared with wild type, whereas AdipoR2-deficient mice were protected from diet-induced weight gain and metabolic perturbations. These data show that AdipoR2, but not AdipoR1, is functionally important in an in vivo model of ischemia-induced revascularization and that its expression is essential for the revascularization actions of adiponectin. These data also show that, in contrast to revascularization responses, AdipoR1, but not AdipoR2 deficiency, leads to diet-induced metabolic dysfunction, revealing that these receptors have highly divergent roles in vascular and metabolic homeostasis.
Sujet(s)
Maladies métaboliques/physiopathologie , Néovascularisation physiologique , Récepteurs à l'adiponectine/physiologie , Animaux , Membres/vascularisation , Souris , Souris knockoutRÉSUMÉ
Brown adipose tissue (BAT) is a highly vascularized organ with abundant mitochondria that produce heat through uncoupled respiration. Obesity is associated with a reduction of BAT function; however, it is unknown how obesity promotes dysfunctional BAT. Here, using a murine model of diet-induced obesity, we determined that obesity causes capillary rarefaction and functional hypoxia in BAT, leading to a BAT "whitening" phenotype that is characterized by mitochondrial dysfunction, lipid droplet accumulation, and decreased expression of Vegfa. Targeted deletion of Vegfa in adipose tissue of nonobese mice resulted in BAT whitening, supporting a role for decreased vascularity in obesity-associated BAT. Conversely, introduction of VEGF-A specifically into BAT of obese mice restored vascularity, ameliorated brown adipocyte dysfunction, and improved insulin sensitivity. The capillary rarefaction in BAT that was brought about by obesity or Vegfa ablation diminished ß-adrenergic signaling, increased mitochondrial ROS production, and promoted mitophagy. These data indicate that overnutrition leads to the development of a hypoxic state in BAT, causing it to whiten through mitochondrial dysfunction and loss. Furthermore, these results link obesity-associated BAT whitening to impaired systemic glucose metabolism.
Sujet(s)
Adipocytes bruns/métabolisme , Tissu adipeux brun/vascularisation , Mitochondries/métabolisme , Obésité/métabolisme , Obésité/anatomopathologie , Adipocytes bruns/anatomopathologie , Tissu adipeux brun/métabolisme , Tissu adipeux brun/anatomopathologie , Animaux , Modèles animaux de maladie humaine , Régulation de l'expression des gènes/génétique , Glucose/génétique , Glucose/métabolisme , Hypoxie/génétique , Hypoxie/métabolisme , Hypoxie/anatomopathologie , Hypoxie/physiopathologie , Souris , Souris knockout , Mitochondries/génétique , Mitochondries/anatomopathologie , Mitophagie/génétique , Obésité/génétique , Obésité/physiopathologie , Espèces réactives de l'oxygène/métabolisme , Facteur de croissance endothéliale vasculaire de type A/biosynthèse , Facteur de croissance endothéliale vasculaire de type A/génétiqueRÉSUMÉ
Peroxisome proliferator-activated receptor gamma (PPARγ) agonists are known to have many immunomodulatory effects. We have previously shown that the PPARγ agonist rosiglitazone is beneficial when used early in prevention of disease in murine models of systemic lupus erythematosus (SLE) and SLE-related atherosclerosis. In this report, we demonstrate that another PPARγ agonist, pioglitazone is also beneficial as a treatment for early murine lupus, indicating that this is a class effect and not agent-specific. We further attempt to define the ability of PPARγ agonists to ameliorate established or severe autoimmune disease using two mouse models: the MRL.lpr SLE model and the gld.apoE(-/-) model of accelerated atherosclerosis and SLE. We demonstrate that, in contrast to the marked amelioration of disease seen when PPARγ agonist treatment was started before disease onset, treatment with rosiglitazone after disease onset in MRL.lpr or gld.apoE(-/-) mice had minimal beneficial effect on the development of the autoimmune phenotype; however, rosiglitazone treatment remained highly effective at reducing lupus-associated atherosclerosis in gld.apoE(-/-) mice after disease onset or when mice were maintained on a high cholesterol Western diet. These results suggest that beneficial effects of PPARγ agonists on the development of autoimmunity might be limited to the early stages of disease, but that atherosclerosis, a major cause of death in SLE patients, may be ameliorated even in established or severe disease.
Sujet(s)
Lupus érythémateux disséminé/traitement médicamenteux , Lupus érythémateux disséminé/prévention et contrôle , Récepteur PPAR gamma/agonistes , Thiazolidinediones/pharmacologie , Animaux , Apolipoprotéines E/déficit , Apolipoprotéines E/immunologie , Lupus érythémateux disséminé/immunologie , Souris , Souris de lignée C57BL , Souris knockout , Récepteur PPAR gamma/immunologie , Pioglitazone , Rosiglitazone , Thiazolidinediones/composition chimique , Thiazolidinediones/usage thérapeutiqueRÉSUMÉ
OBJECTIVE: Despite the clinical prevalence of obesity, only recently has the importance of adipose tissue microenvironment been addressed at a molecular level. Here, I focused on the fat-derived cytokine adiponectin as a model system to understand the mechanism underlying adipose tissue vascularity, perfusion, inflammation, and systemic metabolic function. MATERIALS/METHODS: Wild type, adiponectin-deficient, and adiponectin transgenic-overexpressing mice were maintained on chow diet or high fat/high sucrose diet for 32weeks. Vascularization of adipose tissue was examined by confocal microscopy and perfusion was determined by recovery of injected microspheres. Adipose tissue inflammation and systemic metabolic function were also assessed. RESULTS: Modest over-expression of adiponectin led to a marked increase in adipose tissue vascularity and perfusion, and this was associated with diminished hypoxia and an increase in vascular endothelial growth factor-A (VEGF-A) expression in the obese mice. Adiponectin over-expression in diet-induced obese mice also led to the virtual absence of macrophage infiltration and the elimination of crown-like structures. Adiponectin transgenic mice also displayed a remarkable sensitivity to insulin and diminished hepatic steatosis. Under the conditions of these experiments, adiponectin deficiency did not diminish adipose tissue perfusion or worsen metabolic function compared to wild type mice fed the high fat/high sucrose diet. CONCLUSION: These data demonstrate that increased circulating adiponectin levels, and the obese environment, are associated with increased adipose tissue vascularization and perfusion, and improved metabolic function under conditions of long term diet-induced obesity.
Sujet(s)
Adiponectine/physiologie , Tissu adipeux/vascularisation , Obésité/physiopathologie , Adiponectine/biosynthèse , Adiponectine/génétique , Tissu adipeux/anatomie et histologie , Tissu adipeux blanc/vascularisation , Tissu adipeux blanc/anatomopathologie , Animaux , Régime alimentaire , Hypoxie/métabolisme , Souris , Souris de lignée C57BL , Souris knockout , Microcirculation/physiologie , Microscopie confocale , Microsphères , Néovascularisation physiologique/physiologie , Réaction de polymérisation en chaine en temps réel , Débit sanguin régional/physiologie , Facteur de croissance endothéliale vasculaire de type A/biosynthèseRÉSUMÉ
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is characterized by autoantibody production and inflammatory disease involving multiple organs. Premature atherosclerosis is a common complication of SLE and results in substantial morbidity and mortality from cardiovascular disease (CVD). The reasons for the premature atherosclerosis in SLE are incompletely understood, although chronic inflammation is thought to play an important role. There is currently no known preventative treatment of premature atherosclerosis in SLE. Mycophenolate mofetil (MMF) is an immunosuppressive agent that is commonly used for treatment of patients with SLE. In order to study the impact of this drug on murine lupus disease including premature atherosclerosis development, we treated gld.apoE(-/-) mice, a model of SLE and accelerated atherosclerosis, with MMF. We maintained seven-week old gld.apoE(-/-) mice on a high cholesterol Western diet with or without MMF. After 12 weeks on diet, mice receiving MMF showed decreased atherosclerotic lesion area compared to the control group. MMF treatment also improved the lupus phenotype, indicated by a significant decrease circulating autoantibody levels and ameliorating lupus nephritis associated with this model. This data suggests that the effects of MMF on the immune system may not only be beneficial for lupus, but also for inflammation driving lupus-associated atherosclerosis.
Sujet(s)
Apolipoprotéines E/déficit , Athérosclérose/complications , Athérosclérose/traitement médicamenteux , Ligand de Fas/déficit , Immunosuppresseurs/pharmacologie , Lupus érythémateux disséminé/complications , Acide mycophénolique/analogues et dérivés , Animaux , Athérosclérose/physiopathologie , Autoanticorps/métabolisme , Poids/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Évolution de la maladie , Consommation alimentaire/effets des médicaments et des substances chimiques , Humains , Immunosuppresseurs/usage thérapeutique , Maladies lymphatiques/complications , Maladies lymphatiques/traitement médicamenteux , Souris , Acide mycophénolique/pharmacologie , Acide mycophénolique/usage thérapeutique , Néphrite/complications , Néphrite/traitement médicamenteux , Splénomégalie/complications , Splénomégalie/traitement médicamenteuxRÉSUMÉ
Asthma affects an estimated 300 million people worldwide and accounts for 1 of 250 deaths and 15 million disability-adjusted life years lost annually. Plastic-adherent bone marrow-derived cell (BMC) administration holds therapeutic promise in regenerative medicine. However, given the low cell engraftment in target organs, including the lung, cell replacement cannot solely account for the reported therapeutic benefits. This suggests that BMCs may act by secreting soluble factors. BMCs also possess antiinflammatory and immunomodulatory properties and may therefore be beneficial for asthma. Our objective was to investigate the therapeutic potential of BMC-secreted factors in murine asthma. In a model of acute and chronic asthma, intranasal instillation of BMC conditioned medium (CdM) prevented airway hyperresponsiveness (AHR) and inflammation. In the chronic asthma model, CdM prevented airway smooth muscle thickening and peribronchial inflammation while restoring blunted salbutamol-induced bronchodilation. CdM reduced lung levels of the T(H)2 inflammatory cytokines IL-4 and IL-13 and increased levels of IL-10. CdM up-regulated an IL-10-induced and IL-10-secreting subset of T regulatory lymphocytes and promoted IL-10 expression by lung macrophages. Adiponectin (APN), an antiinflammatory adipokine found in CdM, prevented AHR, airway smooth muscle thickening, and peribronchial inflammation, whereas the effect of CdM in which APN was neutralized or from APN knock-out mice was attenuated compared with wild-type CdM. Our study provides evidence that BMC-derived soluble factors prevent murine asthma and suggests APN as one of the protective factors. Further identification of BMC-derived factors may hold promise for novel approaches in the treatment of asthma.
Sujet(s)
Asthme/prévention et contrôle , Cellules de la moelle osseuse/anatomopathologie , Animaux , Asthme/anatomopathologie , Liquide de lavage bronchoalvéolaire , Mâle , Souris , Souris de lignée BALB CRÉSUMÉ
Adiponectin is a cardioprotective adipokine derived predominantly from visceral fat. We recently demonstrated that exogenous adiponectin induces vascular smooth muscle cell (VSMC) differentiation via repression of mTORC1 and FoxO4. Here we report for the first time that VSMC express and secrete adiponectin, which acts in an autocrine and paracrine manner to regulate VSMC contractile phenotype. Adiponectin was found to be expressed in human coronary artery and mouse aortic VSMC. Importantly, siRNA knock-down of endogenous adiponectin in VSMC significantly reduced the expression of VSMC contractile proteins. Contractile protein deficiency was also observed in primary VSMC isolated from Adiponectin(-/-) mice. This deficiency could be rescued by culturing Adiponectin(-/-) VSMC in conditioned media from wild type (WT) VSMC. Moreover, the paracrine effect of VSMC-derived adiponectin was confirmed as adiponectin neutralizing antibody blocked the rescue. Overexpressed adiponectin also exerted paracrine effects on neighboring untransfected VSMC, which was also blocked by adiponectin neutralizing antibody. Interestingly, adiponectin expression was inducible by the PPARγ agonist rosiglitazone. Our data support an important role for VSMC-derived adiponectin in maintaining VSMC contractile phenotype, contributing to critical cardioprotective functions in the vascular wall. This article is part of a Special Issue entitled "Local Signaling in Myocytes".
Sujet(s)
Adiponectine/métabolisme , Contraction musculaire , Muscles lisses vasculaires/métabolisme , Myocytes du muscle lisse/métabolisme , Communication paracrine , AMP-Activated Protein Kinases/métabolisme , Adiponectine/génétique , Animaux , Réticulum endoplasmique/métabolisme , Femelle , Expression des gènes , Humains , Souris , Souris de lignée C57BL , Souris transgéniques , Contraction musculaire/génétique , Muscles lisses vasculaires/effets des médicaments et des substances chimiques , Myocytes du muscle lisse/effets des médicaments et des substances chimiques , Récepteur PPAR gamma/agonistes , Transport des protéines , Rosiglitazone , Thiazolidinediones/pharmacologieRÉSUMÉ
Inflammation is widely known to play a key role in the development and progression of cardiovascular diseases. It is becoming increasingly evident that obesity is linked to many proinflammatory and obesity-associated cardiovascular conditions (e.g., metabolic syndrome, acute coronary syndrome, and congestive heart failure). It has been observed that adipokines play an increasingly large role in systemic and local inflammation. Therefore, adipose tissue may have a more important role than previously thought in the pathogenesis of several disease types. This review explores the recently described role of adiponectin as an immunomodulatory factor and how it intersects with the inflammation associated with both cardiovascular and autoimmune pathologies.